





The Patent Office Concept House Cardiff Road Newport

REC'D 15 MAY 2002

PCT WIPO

South Wales NP10 8QQ


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before reregistration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely

any to certain additional company law rules.



Signed


Dated

8 February 2002

TTED OR TRANSMITTED IN RULE 17.1(a) OR (b)

An Executive Agency of the Department of Trade and Industry







The Patent Office

Cardiff Road Newport

help you fill in this form)		Gwent NP10 8QQ	
1.	Your reference	4-31671P3	
2.	Patent application number (The Patent Office will fill in this pa	124957.2	777 OCT 200T
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	NOVARTIS AG LICHTSTRASSE 35 4056 BASEL SWITZERLAND	
	Patent ADP number (if you know it)		
	If the applicant is a corporate body, give the country/state of its incorporation		712 548700
4.	Title of invention	Organic Compounds	
5.	Name of your agent (If you have one)	-	
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	B.A. YORKE & CO. CHARTERED PATENT COOMB HOUSE, 7 ST ISLEWORTH MIDDLESEX TW7 6NH	. JOHN'S ROAD
	Patents ADP number (if you know it)	1800001	
6.	If you are declaring priority from one ore more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	nur	pplication Date of filing nber (day/month/year know it))
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day/month/year)
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer Yes' if:	Yes	
	 a) any applicant named in part 3 is not an inventor, or 		
	 there is an inventor who is not named as an applicant, or 		·
	 c) any named applicant is a corporate body. 		
	(see note (d))	•	

Patents Form 1/77



Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

Claim(s)

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

> Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Porke +

B.A. Yorke & Co.

17 October 2001

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. E. Cheetham 020 8560 5847

Warning

After an application for a patent has been filed. the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the united Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 a) 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it. d)
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77



Organic Compounds

The present invention relates to a new use, in particular a new use for a compound group comprising derivatives of rapamycin.

Suitable derivatives of rapamycin include e.g. compounds of formula I

wherein

 R_1 is CH_3 or $C_{3\text{-}6}$ alkynyl, $R_2 \text{ is H or -}CH_2\text{-}CH_2\text{-}OH,$ X is =O or (H,OH) provided that $R_2 \text{ is -}CH_2\text{-}OH \text{ when } R_1 \text{ is }CH_3 \text{ and } X \text{ is =}O.$

Most of the compounds of formula I are either generically or specifically disclosed in WO 94/09010, WO 95/16691 or WO 96/41807, which are incorporated herein by reference, the compound of formula I wherein X is =0, R_1 is 2-pentynyl and R_2 is -CH₂-CH₂-OH being novel and forming part of the invention.

A preferred compound is 40-0-(2-hydroxyethyl)-rapamycin (referred thereafter as Compound A), disclosed as Example 8 in WO 94/09010.

Certain compounds of formula I have, on the basis of observed activity, e.g. binding to macrophilin-12 (also known as FK-506 binding protein or FKBP-12), e.g. as described in WO 94/09010, WO 95/16691 or WO 96/41807, been found to be useful e.g. as immunosuppressant, e.g. in the treatment of acute allograft rejection. It has now been found that Compounds of formula I have potent antiproliferative properties which make them



useful for cancer chemotherapy, particularly of solid tumors, especially of advanced solid tumors. There is still the need to expand the armamentarium of cancer treatment of solid tumors, especially in cases where treatment with anticancer compounds is not associated with disease regression or stabilization.

In accordance with the particular findings of the present invention, there is provided:

- 1.1 A method for treating solid tumors in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula I.
- 1.2 A method for inhibiting growth of solid tumors in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula I.
- 1.3 A method for inducing tumor regression, e.g. tumor mass reduction, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula I.
- 1.4 A method for treating solid tumor invasiveness or symptoms associated with such tumor growth in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula !.
- 1.5 A method for preventing metastatic spread of tumours or for preventing or inhibiting growth of micrometastasis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula I.
- 1.6 A method for the treatment of a disease associated with deregulated angiogenesis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula I.
- 1.7 A method for inhibiting or controlling deregulated angiogenesis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula I.
- 1.8 A method for enhancing the activity of an anticancer agent or for overcoming resistance to an anticancer agent in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula I either concomitantly or sequentially with said anticancer agent.
- 1.9 A method according to 1.8 wherein the anticancer agent is an inhibitor of signal transduction pathways directed either against host cells or processes involved in tumor



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

